Development of a novel anti-HIV-1 agent from within: Effect of chimeric Vpr-containing protease cleavage site residues on virus replication

Human immunodeficiency virus type 1 viral protein R (Vpr) arrests cells in the G2 phase of the cell cycle by inhibiting p34cdc2 activity

1995 • 885 citations

The Vpr protein of human immunodeficiency virus type 1 influences nuclear localization of viral nucleic acids in nondividing host cells.

1994 • 845 citations

Pathogenesis of human immunodeficiency virus infection

1993 • 835 citations

Treatment of Human Immunodeficiency Virus Infection with Saquinavir, Zidovudine, and Zalcitabine

1996 • 758 citations

The human immunodeficiency virus type 1 vpr gene arrests infected T cells in the G2 + M phase of the cell cycle

1995 • 518 citations

THE RETROVIRAL ENZYMES

1994 • 517 citations

The human immunodeficiency virus type 1 vpr gene prevents cell proliferation during chronic infection

1995 • 411 citations

Human immunodeficiency virus type 1 Vpr arrests the cell cycle in G2 by inhibiting the activation of p34cdc2-cyclin B

1995 • 382 citations

Incorporation of Vpr into human immunodeficiency virus type 1 virions: requirement for the p6 region of gag and mutational analysis

1993 • 368 citations

Human immunodeficiency virus vpr product is a virion-associated regulatory protein

1990 • 363 citations

Construction and use of a human immunodeficiency virus vector for analysis of virus infectivity

1990 • 351 citations

The p2 domain of human immunodeficiency virus type 1 Gag regulates sequential proteolytic processing and is required to produce fully infectious virions

1994 • 349 citations

The HIV-1 Protease as a Therapeutic Target for AIDS

1992 • 343 citations

RECOMBINANT TOXINS AS NOVEL THERAPEUTIC AGENTS

1992 • 325 citations

HIV-1 Gag mutants can dominantly interfere with the replication of the wild-type virus

1989 • 299 citations

A mutation in the human immunodeficiency virus type 1 transmembrane glycoprotein gp41 dominantly interferes with fusion and infectivity.

1992 • 275 citations

Human immunodeficiency virus type 1 viral protein R localization in infected cells and virions

1993 • 275 citations

HIV-1 protease specificity of peptide cleavage is sufficient for processing of gag and pol polyproteins

1988 • 269 citations

Mutational analysis of cell cycle arrest, nuclear localization and virion packaging of human immunodeficiency virus type 1 Vpr

1995 • 260 citations

Distinct Effects in Primary Macrophages and Lymphocytes of the Human Immunodeficiency Virus Type 1 Accessory Genes vpr, vpu, and nef: Mutational Analysis of a Primary HIV-1 Isolate

1994 • 237 citations

Producer-cell modification of human immunodeficiency virus type 1: Nef is a virion protein

1996 • 202 citations

Stable expression of transdominant Rev protein in human T cells inhibits human immunodeficiency virus replication.

1992 • 181 citations

Human Immunodeficiency Virus Type 1 Nef Protein Is Incorporated into Virus Particles and Specifically Cleaved by the Viral Proteinase

1996 • 179 citations

Mutagenic analysis of human immunodeficiency virus type 1 Vpr: role of a predicted N-terminal alpha-helical structure in Vpr nuclear localization and virion incorporation

1995 • 176 citations

Macromolecular interactions in the assembly of HIV and other retroviruses

1994 • 174 citations

Human immunodeficiency virus type 1 Vpr protein binds to the uracil DNA glycosylase DNA repair enzyme

1996 • 173 citations

The glucocorticoid receptor type II complex is a target of the HIV-1 vpr gene product.

1995 • 163 citations

Peptide substrates and inhibitors of the HIV-1 protease

1989 • 162 citations

Comparison of the HIV‐1 and HIV‐2 proteinases using oligopeptide substrates representing cleavage sites in Gag and Gag‐Pol polyproteins

1991 • 161 citations

Isolation and Characterization of a Novel Protein (X-ORF Product) from SIV and HIV-2

1988 • 141 citations

The Vif protein of human and simian immunodeficiency viruses is packaged into virions and associates with viral core structures

1995 • 128 citations

Defining the level of human immunodeficiency virus type 1 (HIV-1) protease activity required for HIV-1 particle maturation and infectivity

1995 • 128 citations

Synthetic peptides as substrates and inhibitors of human immune deficiency virus-1 protease.

1988 • 122 citations

Human retroviruses and aids, 1992

1992 • 119 citations

Dual regulation of silent and productive infection in monocytes by distinct human immunodeficiency virus type 1 determinants

1992 • 117 citations

Vpr protein of human immunodeficiency virus type 1 forms cation-selective channels in planar lipid bilayers.

1996 • 116 citations

Targeting foreign proteins to human immunodeficiency virus particles via fusion with Vpr and Vpx

1995 • 115 citations

Development of Drug Resistance to HIV-1 Protease Inhibitors

1995 • 114 citations

Mutagenesis of protease cleavage sites in the human immunodeficiency virus type 1 gag polyprotein

1991 • 109 citations

Characterization of human immunodeficiency virus type 1 Vif particle incorporation

1996 • 101 citations

A transdominant tat mutant that inhibits tat-induced gene expression from the human immunodeficiency virus long terminal repeat.

1990 • 95 citations

Identification of Residues in the N-Terminal Acidic Domain of HIV-1 Vpr Essential for Virion Incorporation

1995 • 83 citations

Biochemical mechanism of HIV-1 Vpr function. Oligomerization mediated by the N-terminal domain.

1994 • 83 citations

Localization of the Vpx packaging signal within the C terminus of the human immunodeficiency virus type 2 Gag precursor protein

1994 • 74 citations

Functional Analysis of HIV-1 Vpr: Identification of Determinants Essential for Subcellular Localization

1995 • 73 citations

New antiviral strategy using capsid-nuclease fusion proteins

1991 • 73 citations

Deletion of sequences upstream of the proteinase improves the proteolytic processing of human immunodeficiency virus type 1.

1991 • 72 citations

Viral Resistance and the Selection of Antiretroviral Combinations

1995 • 70 citations

Mutagenesis of the putative alpha-helical domain of the Vpr protein of human immunodeficiency virus type 1: effect on stability and virion incorporation.

1995 • 68 citations

Human immunodeficiency virus type 1 drug susceptibility during zidovudine (AZT) monotherapy compared with AZT plus 2',3'-dideoxyinosine or AZT plus 2',3'-dideoxycytidine combination therapy. The protocol 34,225-02 Collaborative Group

1996 • 53 citations

Cleavage of p15 protein in vitro by human immunodeficiency virus type 1 protease is RNA dependent

1994 • 50 citations

Comparison of the Human Immunodeficiency Virus Type 1 and 2 Proteases by Hybrid Gene Construction and trans-Complementation

1989 • 48 citations

Rev/RRE-Independent Mason–Pfizer Monkey Virus Constitutive Transport Element-Dependent Propagation of SIVmac239 Vectors Using a Single Round of Replication Assay

1996 • 41 citations

The Carboxy-Terminal Domain Is Essential for Stability and Not for Virion Incorporation of HIV-1 Vpr into Virus Particles

1995 • 33 citations

Closing in on human immunodeficiency virus–1

1996 • 29 citations

Role of Mason-Pfizer Monkey Virus (MPMV) Constitutive Transport Element (CTE) in the Propagation of MPMV Vectors by Genetic Complementation Using Homologous/HeterologousenvGenes

1996 • 28 citations

Inhibition of human and simian immunodeficiency virus protease function by targeting Vpx-protease-mutant fusion protein into viral particles

1996 • 28 citations

Zidovudine and Lamivudine

1995 • 26 citations

Mutation in the primer binding site of the type 1 human immunodeficiency virus genome affects virus production and infectivity.

1992 • 25 citations

Mechanism of inhibition of the retroviral protease by a Rous sarcoma virus peptide substrate representing the cleavage site between the gag p2 and p10 proteins.

1992 • 22 citations

Analysis of HIV-1 Envelope Mutants and Pseudotyping of Replication-Defective HIV-1 Vectors by Genetic Complementation

1992 • 19 citations

Role of the Conserved Dipeptide Gly75 and Cys76 on HIV-1 Vpr Function

1995 • 17 citations

Current HIV Clinical Trial Design Issues

1995 • 15 citations

Rationale and Experience with Reverse Transcriptase Inhibitors and Protease Inhibitors

1995 • 14 citations

Studies of Zidovudine in Combination with Didanosine and Zalcitabine

1995 • 9 citations

Conference Summary: Novel HIV Therapies—From Discovery to Clinical Proof of Concept

1996 • 8 citations

Propagation of SIV Vectors by Genetic Complementation with a HeterologousenvGene

1992 • 8 citations

4.1 Antiretroviral therapies for HIV

1996 • 8 citations